Dexcom (DXCM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$84.46-4.54%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · DXCM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 41.6% |
| Our one-year growth estimate | diamond | 11.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 30.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 28 industry peers · Company calendar date is not available
DXCM — director transition
Dated 2026-09-10
Director — Glenn S. Boehnlein: The filing discloses the appointment of a new independent director to the board, which is a routine governance event and not an executive departure.
Why it matters: The board approved repurchases through December 31, 2027. Reported purchases would show the plan is in use; no purchases would leave it untested.
Supportive ifA company filing says share repurchases under the $1.0 billion plan are complete.
Worry ifA company filing says the plan had no share repurchases by December 31, 2027.
Why it matters: Q3 revenue grew 11% year over year, and Dexcom raised its 2026 revenue outlook. A higher Q4 result would support continued growth.
Supportive ifQ4 revenue is above $1.344 billion and year-over-year growth is at least 11%.
Worry ifQ4 revenue is below $1.344 billion or year-over-year growth falls below 11%.
Why it matters: Stelo is a consumer glucose product, but the results do not show its sales. Growth would show whether the new app helps reach more users.
Supportive ifAfter the redesigned app launch, Dexcom reports more Stelo sales or users.
Worry ifDexcom reports flat or falling Stelo sales or users in its next update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $360 loss on $10,000 · 3.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,261 loss on $10,000 · 22.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.